Massimo Carlo Mauri
Research Subjects
Massimo Carlo Mauri has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
Silvia Paletta
Clinical Psychopharmacology Unit, Department of Neuroscience and Mental Health, Clinical Psychiatry, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via F.Sforza 35, Milan, 20122, Italy
8 shared publicationsA.C. Altamura
7 shared publications- Alessandro Colasanti
Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom
7 shared publications S. Paletta
7 shared publications- Alessandra Reggiori
Clinical Psychopharmacology Unit, Department of Neuroscience and Mental Health, Clinical Psychiatry, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via F.Sforza 35, Milan, 20122, Italy
6 shared publications - Alessio Fiorentini
University of Milan
6 shared publications
Latest Publications
- 19 June 2019
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 58 (9) , 1219-1220
Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242].
- 19 June 2019
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 58 (9) , 1219-1220
Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242].
- 26 September 2018
- Published by Springer Nature
- p. 245-257
Long-Acting Injection for Psychotic Disorder
- 13 September 2018
- Published by Springer Nature
- p. 57-83
Hallucinations in the Substance-Induced Psychosis
- 13 September 2018
- Published by Springer Nature
- p. 57-83
Hallucinations in the Substance-Induced Psychosis
- 13 September 2018
- Published by Springer Nature
- p. 43-56
Chronic Hallucinatory Disorder “an Equivalent” of Delusional Disorder
- 13 September 2018
- Published by Springer Nature
- p. 43-56
Chronic Hallucinatory Disorder “an Equivalent” of Delusional Disorder
- 19 June 2018
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 57 (12) , 1493-1528
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. The rationale for using therapeutic drug monitoring in relation to second-generation antipsychotics is still being discussed at least with regard to the real clinical utility, but there is evidence that it can improve efficacy, especially when patients do not respond or develop side effects using therapeutic doses. Furthermore, drug plasma concentration determinations can be of some utility in medico-legal problems. This review concentrates on the clinical pharmacokinetic data related to clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, sertindole, asenapine, iloperidone, lurasidone, brexpiprazole and cariprazine and briefly considers the main aspects of their pharmacodynamics. Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine, amisulpride, asenapine, iloperidone and lurasidone provide only limited information and there is no direct evidence concerning ziprasidone, aripiprazole, sertindole, brexpiprazole and cariprazine: the few reported investigations need to be confirmed and extended.
- 19 June 2018
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 57 (12) , 1493-1528
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. The rationale for using therapeutic drug monitoring in relation to second-generation antipsychotics is still being discussed at least with regard to the real clinical utility, but there is evidence that it can improve efficacy, especially when patients do not respond or develop side effects using therapeutic doses. Furthermore, drug plasma concentration determinations can be of some utility in medico-legal problems. This review concentrates on the clinical pharmacokinetic data related to clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, sertindole, asenapine, iloperidone, lurasidone, brexpiprazole and cariprazine and briefly considers the main aspects of their pharmacodynamics. Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine, amisulpride, asenapine, iloperidone and lurasidone provide only limited information and there is no direct evidence concerning ziprasidone, aripiprazole, sertindole, brexpiprazole and cariprazine: the few reported investigations need to be confirmed and extended.
- Open Access
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Dual Diagnosis Open Access
- Vol. 1 (4)
Second Generation Antipsychotics in the Treatment of Major Depression
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Dual Diagnosis Open Access
- Vol. 1 (4)
Open AccessSecond Generation Antipsychotics in the Treatment of Major Depression
- Open Access
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Dual Diagnosis Open Access
- Vol. 1 (2)
Drug Induced Psychosis or Schizophrenia?
Cannabis, cocaine, amphetamines and derivative substances so as hallucinogens and other drugs with psychotomimetic properties has reached an extensive misuse often producing psychotic reactions similar to primary psychotic disease like schizophrenia. In particular cannabis and cocaine use by young people has been increased during these years, and the age of first use is dramatically decreased [1,2].
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Dual Diagnosis Open Access
- Vol. 1 (2)
Open AccessDrug Induced Psychosis or Schizophrenia?
Cannabis, cocaine, amphetamines and derivative substances so as hallucinogens and other drugs with psychotomimetic properties has reached an extensive misuse often producing psychotic reactions similar to primary psychotic disease like schizophrenia. In particular cannabis and cocaine use by young people has been increased during these years, and the age of first use is dramatically decreased [1,2].
- Open Access
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Dual Diagnosis Open Access
- Vol. 1 (2)
Emerging Trends and Prevalences in Dual Diagnosis
Dear colleagues: I am very proud to be invited to join as Editorial Board for Dual Diagnosis: Open Access. It is a very interesting journal with an aim to provide rapid and reliable source of information in the mode of original articles, review articles, case reports, and short communications. This scientific publishes all relevant topics in the area of dual diagnosis particularly, Dual Diagnosis, clinical and treatment. The title of Journal is intriguing and topical. The link between substance abuse and psychosis including schizophrenia itself is debated among clinicians, pharmacologists, and it has important social implications.
- 1 January 2016
- Published by Scitechnol Biosoft Pvt. Ltd. in Dual Diagnosis Open Access
- Vol. 1 (2)
Open AccessEmerging Trends and Prevalences in Dual Diagnosis
Dear colleagues: I am very proud to be invited to join as Editorial Board for Dual Diagnosis: Open Access. It is a very interesting journal with an aim to provide rapid and reliable source of information in the mode of original articles, review articles, case reports, and short communications. This scientific publishes all relevant topics in the area of dual diagnosis particularly, Dual Diagnosis, clinical and treatment. The title of Journal is intriguing and topical. The link between substance abuse and psychosis including schizophrenia itself is debated among clinicians, pharmacologists, and it has important social implications.
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S525
P.3.d.076 Paliperidone “long-acting” and plasma levels along 1 year of maintenance therapy in schizophrenia and schizoaffective disorder
- 1 September 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25, S525
P.3.d.076 Paliperidone “long-acting” and plasma levels along 1 year of maintenance therapy in schizophrenia and schizoaffective disorder